- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Mi | Reeves' Autumn Budget targets community health centres and NHS tech outlay | ||
| Mi | Dupixent gains chronic spontaneous urticaria indication in Europe | ||
| Mi | Questions on how new IRA drug prices will affect MFN agreements | ||
| Mi | Novartis axes 550 jobs at Swiss manufacturing site | ||
| Mi | UNICEF and Gavi to widen affordable malaria vaccine access | ||
| Mi | FDA grants accelerated approval for Otsuka's IgAN therapy | ||
| Di | Gilead snaps up Sprint's TREX1 immunotherapy programme for $400m | ||
| Di | UK-developed leukaemia cell therapy to be offered on NHS | ||
| Di | Made Scientific and Cellergy partner to advance CLG-001 | ||
| Di | Novartis secures approval from FDA for Itvisma to treat SMA | ||
| Mo | GLP-1RA Alzheimer's hopes dashed after Novo Nordisk's semaglutide miss | ||
| Mo | Eli Lilly flies the pharma flag in tech-heavy $1tn market cap club | ||
| Mo | Navigating the FDA's import operations for pharmaceuticals and biologics | ||
| Mo | Investors bet on newer technology and indications for CGTs | ||
| Mo | AstraZeneca to expand biomanufacturing in Maryland, US | ||
| Mo | Vaximm and BCME link on oral cancer immunotherapy platform | ||
| Fr | "Reckless and harmful": experts weigh in on CDC's autism-vaccine link stance | ||
| Fr | Early planning, outsourcing and digitalisation to break down CGT CMC barriers | ||
| Fr | Aspen closes $115m in Series C to advance Parkinson's cell therapy | ||
| Fr | Alvotech and Advanz announce EC approval for Gobivaz biosimilar | ||
| 20.11. | CPHI 2025: linker innovation paves the way for a wave of new ADCs | ||
| 20.11. | Merck KGaA eyes new Parkinson's disease assets with $3bn Valo partnership | ||
| 20.11. | Moderna to onshore drug product manufacturing to Massachusetts | ||
| 20.11. | Regeneron's Eylea franchise boosted by pair of FDA approvals | ||
| 20.11. | Novartis taps North Carolina as new manufacturing hub location |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .